Collectively, these data clearly demonstrate that gilteritinib inhibits multiple signaling pathways, including the cell cycle and apoptosis, to exert its antitumor effects in AXL-positive EC, OC, and GC cells in vitro. Here, AXL is linked to gastric cancer.